Familial hypercholesterolemia is an autosomal dominant disease most often caused by loss of function mutations in the low density lipoprotein receptor (LDLR). Loss of both LDLR alleles in homozygous FH (HoFH) results in excessively high levels of plasma cholesterol, xanthomas, premature atherosclerosis, and death in the first decades of life if untreated. Current treatments are largely ineffective for HoFH and more permanent solutions are desperately needed. Liver-directed gene therapy using Adeno-Associated Viral (AAV) vectors is an area of intense research that is very near to achieving meaningful correction of several inherited diseases. While ongoing clinical trials with AAV are showing promising results, conventional (additive) gene therapy has limitations including: transgene silencing, imprecise control of expression levels, immune responses to transgene and capsid protein, and the loss of episomal AAV genomes to cell division. We believe many of these may be solved by a gene editing approach using the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system. Our long-term goal is to refine and optimize our AAV-based gene therapy platform for repair of disease- causing alleles underlying the most severe lipid disorders. Our central hypothesis is that AAV-mediated homologous recombination, in combination with CRISPR/Cas9 directed DNA cleavage, can effectively repair a mutant version of the Ldlr gene with high efficiency.
In Aim 1 we will determine the optimal Cas9 ortholog and guide RNA sequence for AAV-mediated site specific disruption of the Ldlr gene in mouse liver.
In Aim 2, we will use these vectors, along with a recombinant AAV genome harboring a ?repair template? to deliver the functional ?wild type? exon for Ldlr. The extent of editing and correction will be assessed at the genetic as well as phenotypic levels- include changes in plasma lipids and susceptibility to atherosclerosis. Ms. Furgurson's project is an extension of Aim 2 which is focused on correcting a single nucleotide change in the Ldlr gene that underlies FH in humans. Genome editing in liver is challenging since homology directed repair requires cell division, so rates of correction in adult animals or people are expected to be <1%. Ms. Furgurson will pursue a new strategy to correct this mutation through knocking in the Ldlr transgene, as well as an essential gene for hepatocyte viability, expressed in the same cassette. She will simultaneously poison the rest of the liver through CRISPR-mediated deletion of this essential gene, in order to selectively expand the gene-corrected hepatocytes.
This proposal develops a new gene therapy approach for familial hypercholesterolemia through delivery of the CRISPR/Cas9 genome editing system with Adeno-Associated Viral (AAV) vectors. Ms. Furgurson's project will involve correcting a mutation in the low density lipoprotein receptor (Ldlr) gene that underlies FH in humans. Specifically, she will develop new strategies for correction of this mutation through selective expansion of gene- edited hepatocytes in the adult liver.
| Ni, Li; Scott Jr, Larry; Campbell, Hannah M et al. (2018) Atrial-Specific Gene Delivery Using an Adeno-Associated Viral Vector. Circ Res : |
| Pankowicz, Francis P; Barzi, Mercedes; Kim, Kang Ho et al. (2018) Rapid Disruption of Genes Specifically in Livers of Mice Using Multiplex CRISPR/Cas9 Editing. Gastroenterology 155:1967-1970.e6 |
| Jarrett, Kelsey E; Lee, Ciaran; De Giorgi, Marco et al. (2018) Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research. Arterioscler Thromb Vasc Biol 38:1997-2006 |
| Pan, Xiaolu; Philippen, Leonne; Lahiri, Satadru K et al. (2018) In Vivo Ryr2 Editing Corrects Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Res 123:953-963 |
| Jarrett, Kelsey E; Lee, Ciaran M; Yeh, Yi-Hsien et al. (2017) Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep 7:44624 |
| Pankowicz, Francis P; Jarrett, Kelsey E; Lagor, William R et al. (2017) CRISPR/Cas9: at the cutting edge of hepatology. Gut 66:1329-1340 |
